Overview
Dr. Georgia Tomaras is a tenured Professor of Surgery, Professor of Immunology, Professor of Molecular Genetics and Microbiology and is a Fellow of the American Academy of Microbiology (AAM) and a Fellow of the American Association for the Advancement of Science (AAAS). Dr. Tomaras is Co-Director of the Center for Human Systems Immunology (CHSI) Duke University and Director of the Duke Center for AIDS Research (CFAR). Her national and international leadership roles include: Executive Management Team (EMT) leader and mPI for the HIV Vaccine Trials Network (HVTN); Director of Lab Sciences (HVTN); and Chair of NIH Vaccine Research Center (VRC) Board of Scientific Counselors. Her prior leadership roles include serving as the Director of Research, Duke Human Vaccine Institute (DHVI); Director of the DHVI Training Program; Associate Director of DHVI Research; Co-Director of the Interdisciplinary Research Training Program in AIDS (IRTPA) Duke; Chair of the National Institutes of Health (NIH) AIDS Vaccine Research Subcommittee (AVRS), and Advisory Counsel member of the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). Dr. Tomaras’ primary research focus is deciphering mechanisms of protective human immunity and identification of immune correlates of protection to further development of effective vaccines against infectious diseases.
Current Appointments & Affiliations
Recent Publications
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
Journal Article J Virol · December 23, 2025 UNLABELLED: HIV-1 continues to pose a significant global health challenge, requiring ongoing research into effective prevention and treatment strategies. Understanding the B-cell repertoire that can be engaged upon vaccination in humans is crucial for the ... Full text Link to item CiteHydrogel formulations for sustained-release of broadly neutralizing antibodies.
Journal Article J Control Release · December 10, 2025 Sustained serum levels of broadly neutralizing antibodies (bnAbs) are crucial for effective passive immunization against infectious diseases as protection persists only while these bnAbs remain at adequate concentrations within the body. Current obstacles, ... Full text Link to item CiteA polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.
Journal Article Emerg Microbes Infect · December 2025 Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any effi ... Full text Link to item CiteRecent Grants
Nonhuman Primate Core-Option 6
ResearchInvestigator · Awarded by National Institutes of Health · 2025 - 2032Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2030Multiscale Modeling of Influenza Neutralizing Antibody and Fc Effector Biology
ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2029View All Grants
Education, Training & Certifications
External Links
Duke Immunologist Q&A Duke Led Team -Accurate tool to track HIV infections Duke Research Prize ALICE leadership Duke highly cited Elected Fellow Tomaras Lab leaders Yates and Seaton CHSI leadership at Duke HIV Vaccine Trials Network Leadership Duke scientists find potent antibody to HIV-1 Duke Identifies Shortcomings In HIV Vaccine